CHM chimeric therapeutics limited

Ann: Phase 1B CHM CORE-NK trial advances to newly diagnosed AML, page-5

  1. 1,298 Posts.
    lightbulb Created with Sketch. 3957
    It only took 6 patients (Estimated was 6-12) across 2 dose finding cohorts "to establish a recommended phase 2 dose (RP2D) using a BOIN design."

    Looking at the 2024 Deliverables:

    https://hotcopper.com.au/data/attachments/6678/6678887-f12e4dd26f6df1a0a9c921dfff4bc838.jpg

    Highlighted ones are yet to be completed.

    2 clinical data announcements expected in the short term (~6 weeks), one of them depending on a CDH17 1st dose cohort completion announcement yet to come as well.

    It is shaping up for a very interesting calendar year 2025!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.5¢ 0.5¢ 0.4¢ $432 98K

Buyers (Bids)

No. Vol. Price($)
26 22188206 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 25892021 31
View Market Depth
Last trade - 13.15pm 16/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.